Intestinal Metaplasia of Gastric MucosaArtificial IntelligenceEndoscopy
Investigational drug(s) / intervention(s)
The diagnostic performance of AI system and endoscopists
The diagnostic performance of AI system and endoscopists: Eligible patients will undergo independent EGGIM score assessment by both endoscopists and the AI system.
Study summary
The endoscopic grading system (EGGIM) has been widely used to assess the extent of gastric intestinal metaplasia during endoscopy. Investigators developed an artificial intelligence (AI) system to automatically evaluate the extent of gastric intestinal metaplasia (GIM) and calculate the EGGIM scores in endoscopy examination. This study is a prospective, multi-center study aimed at exploring the performance and reliability of AI-EGGIM scoring.
This is a prospective study designed to validate the AI-EGGIM system in a larger cohort. The study protocol was developed based on preliminary experience from a prior investigation (NCT05464108).
Eligibility
Sex
ALL
Min age
40 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* patients aged 40-75 years who undergo the IEE examination
* patients who voluntarily sign the informed consent form
Exclusion Criteria:
* patients with severe cardiac, cerebral, pulmonary or renal dysfunction or psychiatric disorders who cannot participate in gastroscopy
* patients with previous surgical procedures on the stomach
Primary outcome measure(s)
Performance of AI system to diagnose the grade of intestinal metaplasia by calculating the EGGIM score — 1 year The performance of the AI system will be evaluated in diagnosing the grade of gastric intestinal metaplasia (IM) based on the Endoscopic Grading of Gastric Intestinal Metaplasia (EGGIM) system. EGGIM is a validated scoring method ranging from 0 to 10, reflecting the extent of IM across five gastric regions: two in the antrum, two in the corpus, and one at the incisura. Each region is scored as 0 (no IM), 1 (focal IM, ≤30% of the area), or 2 (extensive IM, \>30% of the area), with a total possible score of 10. Higher EGGIM scores correspond to more severe IM and greater gastric cancer risk. The AI-derived scores will be compared with expert' EGGIM scores, which serve as the gold standard, to assess diagnostic accuracy.
Trial sites (3)
Facility
City
Region
Status
Qilu Hospital of Shandong University
Jinan
Shandong
Recruiting
Shandong First Medical University First Affiliated Hospital
Jinan
Shandong
Not Yet Recruiting
Shandong Second Provincial General Hospital
Jinan
Shandong
Not Yet Recruiting
More Qilu Hospital of Shandong University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.